Log in

CEL-SCI Stock Forecast, Price & News

+1.61 (+12.65 %)
(As of 09/18/2020 12:00 AM ET)
Today's Range
Now: $14.34
50-Day Range
MA: $13.96
52-Week Range
Now: $14.34
Volume2.80 million shs
Average Volume833,044 shs
Market Capitalization$553.87 million
P/E RatioN/A
Dividend YieldN/A
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation was founded in 1983 and is headquartered in Vienna, Virginia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.8Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.06 out of 5 stars

Industry, Sector and Symbol

Industry Biotechnology



Sales & Book Value

Annual SalesN/A



Market Cap$553.87 million
Next Earnings Date12/21/2020 (Estimated)
+1.61 (+12.65 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CVM News and Ratings via Email

Sign-up to receive the latest news and ratings for CVM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

CEL-SCI (NYSEAMERICAN:CVM) Frequently Asked Questions

How has CEL-SCI's stock price been impacted by COVID-19 (Coronavirus)?

CEL-SCI's stock was trading at $9.74 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, CVM stock has increased by 47.2% and is now trading at $14.34.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of CEL-SCI?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for CEL-SCI in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for CEL-SCI

When is CEL-SCI's next earnings date?

CEL-SCI is scheduled to release its next quarterly earnings announcement on Monday, December 21st 2020.
View our earnings forecast for CEL-SCI

How were CEL-SCI's earnings last quarter?

CEL-SCI Co. (NYSEAMERICAN:CVM) posted its earnings results on Tuesday, August, 11th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $0.12. The company earned $0.20 million during the quarter, compared to analyst estimates of $0.10 million.
View CEL-SCI's earnings history

What price target have analysts set for CVM?

1 analysts have issued 1 year price objectives for CEL-SCI's shares. Their forecasts range from $23.00 to $23.00. On average, they anticipate CEL-SCI's share price to reach $23.00 in the next twelve months. This suggests a possible upside of 60.4% from the stock's current price.
View analysts' price targets for CEL-SCI

Who are some of CEL-SCI's key competitors?

What other stocks do shareholders of CEL-SCI own?

Who are CEL-SCI's key executives?

CEL-SCI's management team includes the following people:
  • Mr. Geert R. Kersten, CEO, Principal Accounting & Financial Officer, Treasurer and Director (Age 60)
  • Ms. Patricia B. Prichep, Sr. VP of Operations & Corp. Sec. (Age 68)
  • Dr. Eyal Talor, Chief Scientific Officer (Age 63)
  • Dr. Daniel H. Zimmerman, Sr. VP of Research & Cellular Immunology (Age 78)
  • Mr. John Cipriano, Sr. VP of Regulatory Affairs (Age 77)

What is CEL-SCI's stock symbol?

CEL-SCI trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "CVM."

Who are CEL-SCI's major shareholders?

CEL-SCI's stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.36%), Goldman Sachs Group Inc. (1.41%), D.A. Davidson & CO. (0.63%), Commonwealth Equity Services LLC (0.63%), Bank of New York Mellon Corp (0.40%) and Nuveen Asset Management LLC (0.35%). Company insiders that own CEL-SCI stock include Daniel H Zimmerman, Geert R Kersten, John Cipriano, Patricia B Prichep and Peter R Young.
View institutional ownership trends for CEL-SCI

Which major investors are selling CEL-SCI stock?

CVM stock was sold by a variety of institutional investors in the last quarter, including D.A. Davidson & CO., Virtus ETF Advisers LLC, AQR Capital Management LLC, Nuveen Asset Management LLC, Charles Schwab Investment Management Inc., Thoroughbred Financial Services LLC, and IFP Advisors Inc.
View insider buying and selling activity for CEL-SCI

Which major investors are buying CEL-SCI stock?

CVM stock was bought by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Swiss National Bank, Alps Advisors Inc., SG Americas Securities LLC, Virtu Financial LLC, Rafferty Asset Management LLC, Neuberger Berman Group LLC, and Bank of New York Mellon Corp. Company insiders that have bought CEL-SCI stock in the last two years include Geert R Kersten, Patricia B Prichep, and Peter R Young.
View insider buying and selling activity for CEL-SCI

How do I buy shares of CEL-SCI?

Shares of CVM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is CEL-SCI's stock price today?

One share of CVM stock can currently be purchased for approximately $14.34.

How big of a company is CEL-SCI?

CEL-SCI has a market capitalization of $553.87 million.

What is CEL-SCI's official website?

The official website for CEL-SCI is www.cel-sci.com.

How can I contact CEL-SCI?

CEL-SCI's mailing address is 8229 Boone Blvd Ste 802, VIENNA, VA 22182-2634, United States. The company can be reached via phone at +1-703-5069460.

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.